Full Press Release Details
TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting.
HURA
TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting
Key Takeaway: TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting
Price reaction · baseline $3.06 (2025-05-30 close) · 1 other HURA headline(s) in the window, move may be shared
day 0 close · peak
+2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+457%
120-day peak, hindsight
Typical move
7%
average across 2 past catalysts
Cash runway
~0 mo
High dilution risk
Lead asset
dalazatide
Phase 1 · Plaque Psoriasis